Anti-TnC-A1 Immunocytokine, scFv (F16)-IL2

Business Offer

2017/07/31

United States

This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-TnC-A1 scFv to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the TnC-A1 as well as the biological activity of IL2. This fusion of cytokine to antibody fragment scFv allows for a targeted delivery and improves efficacy and pharmacokinetics. This immunocytokine was designed for treating solid tumors.

This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-TnC-A1 scFv to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the TnC-A1 as well as the biological activity of IL2. This fusion of cytokine to antibody fragment scFv allows for a targeted delivery and improves efficacy and pharmacokinetics. This immunocytokine was designed for treating solid tumors. http://www.creativebiolabs.net/Anti-TnC-A1-Immunocytokine-scFv-F16-IL2-22493.htm

[RequestAdvantages]

[RequestComments]

381

Creative Biolabs